The 2-day program at the Gaylord Opryland Resort will bring together established and emerging eye care leaders for sessions on leadership development, artificial intelligence, inclusion, and career growth.
|Podcasts|July 26, 2021
Evaluating safety, efficacy of TP03 for Demodex blepharitis treatment
Author(s)Elizabeth Yeu, MD, Alex Delaney-Gesing
Elizabeth Yeu, MD, shares results from the Saturn 1 pivotal phase 2b3 trial evaluating the safety and efficacy of TP03 for the treatment of patients diagnosed with Demodex blepharitis.
Advertisement
Elizabeth Yeu, MD, a cornea cataract and refractive surgeon at Virginia Eye Consultants, shares results from the Saturn 1 pivotal phase 2b3 trial evaluating the safety and efficacy of a new investigational therapeutic from Tarsus Pharmaceuticals called TP03 (lotilaner ophthalmic solution 0.25%), for the treatment of patients diagnosed with Demodex blepharitis.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Uveitis: a practical guide for ophthalmologists and optometrists
2
FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia
3
Varicose veins linked to central serous chorioretinopathy in large cohort study
4
AAO 2026: How to become an ocular pain detective in dry eye
5